publication date: Jun. 30, 2016

Leukemia and Lymphoma Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting


AbbVie published longer-term follow-up results from three phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: RESONATE, RESONATE-2 and HELIOS.

These data were presented at the annual meeting of the American Society of Clinical Oncology. Imbruvica is jointly developed and commercialized in the U.S. by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc.

“Our clinical data presented at this year’s ASCO from several randomized studies demonstrate solid durability of response with Imbruvica in patients with CLL/SLL with additional follow-up of up to three years,” said Danelle James, head of oncology at Pharmacyclics.

An analysis of the RESONATE and RESONATE-2 trials showed Imbruvica was associated with favorable PFS and OS outcomes, as well as a high overall response rate in previously treated and treatment-naïve patients with CLL/SLL, regardless of line of therapy. The median PFS and OS were not reached in treatment-naïve or previously-treated patients; 89 to 92 percent of patients treated with Imbruvica at first or second line of therapy remained progression-free at two years. Additionally, ORR was high in both previously treated and treatment-naïve patients (92 and 91 percent, respectively).

The safety profile was similar for both patient groups and was consistent with previously-reported outcomes. Data from the RESONATE and RESONATE-2 studies … Continue reading CCL June 2016 – Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.